Classification
Product TypeIngredient
Product FormFreeze-dried microbial culture (powder) for food supplement/food use
Industry PositionFunctional ingredient (probiotic culture) used in food supplements and functional foods
Market
In Great Britain (GB), Lactobacillus-containing products are typically placed on the market as foods/food supplements and must comply with GB food law, including strict rules on nutrition and health claims. Marketing that presents a product as preventing or treating disease, or that implies a medicinal purpose, can trigger MHRA assessment as a borderline medicine. “Probiotic” and gut-health style messaging is treated as likely within scope of the GB nutrition and health claims framework, meaning only authorised claims on the GB NHC register can be used in relevant contexts. Where a specific strain (or production process) lacks a demonstrated history of consumption before 15 May 1997, a GB novel foods status assessment and potential authorisation may be needed before sale.
Market RoleDomestic consumer and formulation market for probiotic-containing food supplements and functional foods
Domestic RolePrimarily used as an ingredient in dose-form food supplements and in certain functional/fermented food applications sold in GB
Specification
Physical Attributes- Freeze-dried (lyophilised) powder or blended premix intended for encapsulation/tableting/sachet filling
- Moisture and oxygen sensitivity management (barrier packaging and desiccant use) is a common handling requirement to protect viability
Compositional Metrics- Viable count (e.g., CFU) targets typically specified at end of shelf life, with agreed test method and storage conditions
- Microbiological safety criteria typically include absence of specified pathogens and defined limits for contaminants, supported by batch COA
Packaging- Moisture/oxygen barrier bulk packaging (e.g., foil laminate bags) with desiccant; secondary protective packaging for transit
- Cold-pack/insulated shipping may be used depending on strain stability profile and supplier specifications
Supply Chain
Value Chain- Strain selection and controlled cultivation/fermentation → concentration → freeze-drying → bulk packaging → (GB) blending/encapsulation/packaging by supplement manufacturer or contract manufacturer → distribution
Temperature- Temperature excursions can reduce viable counts; shipment and storage conditions are typically defined in supplier specifications to protect viability
Atmosphere Control- Moisture/oxygen exposure control (sealed barrier packs; rapid reseal after sampling) supports viability retention
Shelf Life- Shelf-life performance is commonly expressed as meeting a minimum viable count at end-of-life under declared storage conditions
Freight IntensityLow
Transport ModeMultimodal
Risks
Regulatory Compliance HighMarket access can be blocked or severely disrupted if the product’s claims/presentation cause it to be treated as a medicine (borderline) or if a specific strain/process is deemed a novel food without GB authorisation; “probiotic” and gut-health messaging is closely scrutinised under GB nutrition and health claims rules and advertising guidance.Run pre-launch regulatory review of claims and presentation (food vs medicine); verify strain novelty status early (FSA Article 4/authorisation routes where needed); restrict claims to those permitted on the GB NHC register and follow CAP/ASA guidance.
Food Safety MediumContamination, misidentification of strain, or failure to meet declared viable count at end of shelf life can trigger customer rejection, withdrawals, and enforcement attention, especially in dose-form supplement products.Use qualified suppliers with strong food safety certification; require COA per batch (identity, pathogens/contaminants, viability) and stability data supporting end-of-life CFU under stated storage.
Logistics MediumTemperature and humidity excursions during transport or warehousing can reduce viability, leading to non-compliance with label declarations and contract specifications.Define shipping/storage conditions in specifications; use moisture/oxygen barrier packaging and appropriate thermal protection; monitor storage conditions and apply FEFO inventory management.
Standards- BRCGS Global Standard Food Safety (commonly used as a third-party food safety management certification framework in GB-facing supply chains)
- HACCP-based food safety management systems (commonly expected by retailers/importers for food ingredient and supplement supply)
FAQ
Can Lactobacillus supplements be marketed in Great Britain with “probiotic” or gut-health claims?Claims are tightly controlled in GB: only authorised nutrition and health claims on the Great Britain NHC register may be used when the claims rules apply. CAP/ASA guidance indicates that “probiotic” claims are likely within scope, and whether they are acceptable depends on how they are presented and whether any required accompanying authorised claims (and conditions of use) are met.
When would a Lactobacillus strain need novel foods authorisation in Great Britain?If the specific strain (or the way it is produced) does not have evidence of significant consumption in the UK or EU before 15 May 1997, it may be considered a novel food and must be authorised before it can be placed on the GB market. The Food Standards Agency provides guidance and routes to assess novelty status (Article 4) and to apply for authorisation.
When could a Lactobacillus product be treated as a medicine instead of a food supplement in Great Britain?If the product is presented as preventing or treating disease, or if its claims and overall presentation lead to it being considered to modify physiological function by pharmacological, immunological or metabolic action, the MHRA may consider it a borderline medicinal product. This risk is driven heavily by the claims made in labelling, advertising, and other marketing materials.